UK markets close in 3 hours 39 minutes
  • FTSE 100

    7,786.39
    +14.69 (+0.19%)
     
  • FTSE 250

    20,006.98
    +153.53 (+0.77%)
     
  • AIM

    874.32
    +6.50 (+0.75%)
     
  • GBP/EUR

    1.1311
    -0.0028 (-0.25%)
     
  • GBP/USD

    1.2317
    +0.0000 (+0.00%)
     
  • BTC-GBP

    18,750.65
    +80.42 (+0.43%)
     
  • CMC Crypto 200

    523.31
    +4.52 (+0.87%)
     
  • S&P 500

    4,076.60
    +58.83 (+1.46%)
     
  • DOW

    34,086.04
    +368.95 (+1.09%)
     
  • CRUDE OIL

    79.42
    +0.55 (+0.70%)
     
  • GOLD FUTURES

    1,945.10
    -0.20 (-0.01%)
     
  • NIKKEI 225

    27,346.88
    +19.77 (+0.07%)
     
  • HANG SENG

    22,072.18
    +229.85 (+1.05%)
     
  • DAX

    15,162.14
    +33.87 (+0.22%)
     
  • CAC 40

    7,094.50
    +12.08 (+0.17%)
     

Wolters Kluwer acquires NurseTim

Wolters Kluwer acquires NurseTim

Enhances portfolio of nursing education solutions

Alphen aan den Rijn, January 9, 2023 — Wolters Kluwer Health today announced it has signed and completed an agreement to acquire NurseTim, a US-based provider of nursing education solutions.

NurseTim will become part of Wolters Kluwer’s Health Learning, Research & Practice (HLRP) business, which includes nursing education and practice solutions that help ensure students are ready for practice and nurses are prepared to deliver better patient care and outcomes.

NurseTim’s NurseThink provides a set of test preparation tools for faculty and students to prepare candidates for the Next Generation National Council Licensure Examination (NCLEX) in the U.S. In addition, the company provides hands-on nurse faculty training through conferences and webinars.

“Combining our nursing education portfolio and NurseTim will create a comprehensive suite of solutions that generates greater value for our customers,” commented Julie Stegman, Vice President of the Health LRP Nursing Segment at Wolters Kluwer. “NurseTim’s focus on faculty preparation and nurse clinical judgement training aligns well with our existing focus on ensuring nurses are clinically competent and prepared to practice.”

“For over 15 years, NurseTim has been known as a leader in innovation in nursing education and practice readiness. Through the creation of strategies and tools that are accessible to faculty and students, NurseTim is ushering the industry into a new era. We are excited by Wolters Kluwer’s proven success with its Lippincott solutions and positive impact on the profession. This track record and our shared commitment to nursing program outcomes and student success make it a good fit for the next phase of growth for NurseTim,” commented Tim Bristol, CEO, NurseTim Inc.

NurseTim, founded in 2008, is based in Minneapolis MN and employs 48 professionals. Wolters Kluwer expects the investment to deliver a return on invested capital (ROIC) above its weighted average cost of capital (8%) within 3-5 years and expects the transaction to have an immaterial impact on adjusted earnings.

About Wolters Kluwer
Wolters Kluwer (EURONEXT: WKL) is a global leader in professional information, software solutions, and services for the healthcare; tax and accounting; governance, risk and compliance; and legal and regulatory sectors. We help our customers make critical decisions every day by providing expert solutions that combine deep domain knowledge with specialized technology and services.

Wolters Kluwer reported 2021 annual revenues of €4.8 billion. The group serves customers in over 180 countries, maintains operations in over 40 countries, and employs approximately 20,000 people worldwide. The company is headquartered in Alphen aan den Rijn, the Netherlands.

Wolters Kluwer shares are listed on Euronext Amsterdam (WKL) and are included in the AEX and Euronext 100 indices. Wolters Kluwer has a sponsored Level 1 American Depositary Receipt (ADR) program. The ADRs are traded on the over-the-counter market in the U.S. (WTKWY).

For more information, visit www.wolterskluwer.com, follow us on LinkedInTwitter, Facebook, and YouTube.

Media

 

Investors/Analysts

Gerbert van Genderen Stort

André Rebelo

Meg Geldens

Corporate Communications

Wolters Kluwer Health

Investor Relations

t + 31 172 641 230

t +1 781 392 2411

t + 31 172 641 407

press@wolterskluwer.com

andre.rebelo@wolterskluwer.com

ir@wolterskluwer.com

Forward-looking Statements and Other Important Legal Information
This report contains forward-looking statements. These statements may be identified by words such as “expect”, “should”, “could”, “shall” and similar expressions. Wolters Kluwer cautions that such forward-looking statements are qualified by certain risks and uncertainties that could cause actual results and events to differ materially from what is contemplated by the forward-looking statements. Factors which could cause actual results to differ from these forward-looking statements may include, without limitation: general economic conditions; conditions in the markets in which Wolters Kluwer is engaged; behavior of customers, suppliers, and competitors; technological developments; the implementation and execution of new ICT systems or outsourcing; and legal, tax, and regulatory rules affecting Wolters Kluwer’s businesses, as well as risks related to mergers, acquisitions, and divestments. In addition, financial risks such as currency movements, interest rate fluctuations, liquidity, and credit risks could influence future results. The foregoing list of factors should not be construed as exhaustive. Wolters Kluwer disclaims any intention or obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Certain trademarks referenced are owned by Wolters Kluwer N.V. and its subsidiaries and may be registered in various countries.

 

Attachment